BioArctic AB is a Swedish biotechnology company founded in 2003, headquartered in Stockholm, Sweden. The company specializes in developing novel treatments for neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease. BioArctic is known for its expertise in protein aggregation, specifically amyloid-beta and alpha-synuclein, and its partnership with Eisai Co., Ltd. for the development of lecanemab (Leqembi). [1]
BioArctic was founded in 2003 by a team of scientists from the Karolinska Institute, led by Professor Lars Lannfelt, who pioneered research on the role of amyloid-beta in Alzheimer's disease. The company's foundational science originated from the discovery of the Arctic APP mutation (Appena23) that was identified in a Swedish family and shown to enhance amyloid-beta aggregation in vitro[2].
| Year | Milestone |
|---|---|
| 2003 | Founded in Stockholm, Sweden by Professor Lars Lannfelt |
| 2007 | Strategic partnership with Eisai initiated for amyloid-beta research |
| 2015 | IPO on Nasdaq Stockholm (OMXS: BIOA B) |
| 2021 | Lecanemab received accelerated approval from FDA |
| 2023 | Full approval granted for early Alzheimer's disease |
| 2024 | Continued expansion of Parkinson's disease pipeline |
BioArctic's scientific platform centers on understanding the misfolding and aggregation of neurodegenerative disease-related proteins:
Amyloid-Beta (Aβ)
Alpha-Synuclein
BioArctic has developed proprietary technology to enhance drug delivery to the brain:
| Drug | Mechanism | Phase | Partner | Status |
|---|---|---|---|---|
| Lecanemab (Leqembi) | Anti-Aβ Protofibril | Approved | Eisai | Marketed in US, EU, Japan |
| BAN2401 | Anti-Aβ Protofibril | Phase 3 | Eisai | CLARITY-AD completed |
| AB0090 | Next-gen anti-Aβ | Preclinical | Eisai | IND-enabling |
Lecanemab (Leqembi) is BioArctic's most advanced program. This anti-amyloid-beta monoclonal antibody specifically targets and clears amyloid-beta protofibrils, which are believed to be the most toxic form of the protein. The drug received accelerated approval in January 2023 and full approval in July 2023 from the FDA for treatment of early Alzheimer's disease[3].
The CLARITY-AD phase 3 trial demonstrated significant slowing of cognitive decline in patients with early Alzheimer's disease, with the most common adverse events being amyloid-related imaging abnormalities (ARIA)[4].
| Drug | Mechanism | Phase | Status |
|---|---|---|---|
| AB0010 (CLS-010) | Alpha-synuclein Antibody | Phase 1 | Active |
| AB0020 | Alpha-synuclein Oligomer Inhibitor | Preclinical | Discovery |
AB0010 (CLS-010) is BioArctic's lead Parkinson's disease program. This monoclonal antibody targets alpha-synuclein and is designed to prevent the spread of pathological alpha-synuclein species between neurons[5]. The Phase 1 study is evaluating safety and tolerability in patients with early Parkinson's disease.
BioArctic's most significant partnership is with Eisai Co., Ltd., a leading Japanese pharmaceutical company. This strategic collaboration has been instrumental in advancing BioArctic's Alzheimer's disease pipeline:
Key Terms:
Collaboration History:
BioArctic maintains active collaborations with leading academic institutions:
| Quarter | Key Events |
|---|---|
| Q1 2024 | Lecanemab sales growth, AB0010 Phase 1进展 |
| Q2 2024 | Regulatory submissions in additional markets |
| Q3 2024 | Pipeline expansion announcement |
| Q4 2024 | Partnership milestone payments |
The CLARITY-AD trial was a randomized, double-blind, placebo-controlled Phase 3 study enrolling 1,795 patients with early Alzheimer's disease[3:1]:
Primary Endpoint Results:
Key Secondary Endpoints:
The main safety concerns for lecanemab relate to amyloid-related imaging abnormalities (ARIA):
BioArctic occupies a unique position in the neurodegenerative disease therapeutic landscape:
BioArctic's strategic priorities include:
Protein aggregation in neurodegenerative disease. Nature Reviews Neuroscience. 2020. ↩︎
Lecanemab for Early Alzheimer's Disease. Nature Reviews Neurology. 2023. ↩︎ ↩︎
BAN2401 in early Alzheimer's disease. Alzheimer's & Dementia. 2022. ↩︎
CLS-010 (AB0010) Phase 1 Study in Parkinson's Disease. Movement Disorders. 2024. ↩︎